| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.009 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.087 | 0.009 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.009 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.01 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.1 | 0.01 |